Last updated: 2026-10-13 16:17:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Aquestive Therapeutics, Inc. (AQST) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.73, with a market capitalisation of $599.95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.93 to $7.55. This page covers its latest market performance, valuation, price trends and company information.
$599.95M | |
$4.80 | |
$20.70 | |
$0.62 | |
$4.81 | |
542.47K | |
2.68M | |
-- | |
$7.55 | |
$2.93 | |
-- | |
-- |
Aquestive Therapeutics, Inc. (AQST) is currently trading at $4.73 as of 2026-10-13 16:00:54, down 1.77% ($0.08) from the previous close of $4.81
During today's regular trading session, AQST has traded between $0.62 and $20.70, with a trading volume of 542.47K shares. The current price is near the lower end of today's range.
Over the past seven days, Aquestive Therapeutics, Inc. (AQST) moved from $4.55 to $4.73, representing a gain of 3.85% ($0.17).
The stock traded between $4.43 and $4.98 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1.56 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38.9%
AQST is currently trading at $4.73, placing it 38.9% of the way from its 52-week low of $2.93 to its 52-week high of $7.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 147 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aquestive Therapeutics, Inc. (AQST) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.